GlobeNewswire
-
Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
10/11/2026 -
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
10/11/2026 -
In Light of New FDA Warning for GLP-1s, Doctors Offer Research-Backed Dietary Intervention for Weight Loss
10/11/2026 -
Two-thirds of Canadians on fertility journeys regret waiting to get help, one in three unsure of where to begin: new data
10/11/2026 -
Researchers Demonstrate that Dynamic Digital Radiography Provides Quantitative Assessment of Shoulder Kinematics Accurately and More Consistently Than Currently Accepted Methods
10/11/2026 -
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
10/11/2026 -
Nelipak Healthcare Packaging Acquires Technipaq, Inc.
10/11/2026 -
JenaValve Presents Late-Breaking JENA-VAD Data at TCT 2026, Demonstrating High Technical Success and 30 Day Safety of the Trilogy System in LVAD Patients Under IDE
10/11/2026 -
Metabolon Expands Verus™ Metabolomics Profiling Kit Availability to Europe and Adds New Rodent Sample Types
10/11/2026 -
HealthEx Partners with Oscar Insurance to Bring Members’ Medical Records Into the Oscar App
10/11/2026 -
Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026
10/11/2026 -
Alpha Pro Tech, Ltd. Announces Third Quarter 2026 Financial Results
10/11/2026 -
Nu-Tek BioSciences passe avec succès l’audit de certification ISO 9001, renforçant ainsi son engagement en faveur de la qualité des matières premières
10/11/2026 -
Nu-Tek BioSciences Successfully Completes ISO 9001 Certification Review, Reinforcing Commitment to Raw Material Quality
10/11/2026 -
Franciscan Health and Ossium Health Perform World's First Organ Donor Bone Marrow Transplant for Non-Malignant Disease
10/11/2026 -
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
10/11/2026 -
TETmedical Appoints Dr. Hooman Kamel and Dr. Evan Gerber as Medical Advisors
10/11/2026 -
Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
10/11/2026 -
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026
Pages